BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
ClinicalTrials.gov ID: NCT06265350
What this study is testing
What is Cadonilimab?
Cadonilimab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for hepatocellular carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- primary or recurrent HCC;
- synchronous metastases (within one month after diagnosing of HCC) or asynchronous metastases (more than one month after diagnosis of HCC);
- pulmonary-only metastases \>5 and ≤10;
- metastases diameter ≤ 5 cm;
- intrahepatic tumors ≤5, and tumor burden ≤1/2 liver volume;
You likely can't join if
- under 18 years or over 75 years;
- metastases \>10
- non-lung metastases;
- incomplete clinical data;
- metastases diameter \> 5 cm;
- intrahepatic tumors \> 5, and tumor burden \> 1/2 liver volume;
See the full eligibility criteria
- primary or recurrent HCC;
- synchronous metastases (within one month after diagnosing of HCC) or asynchronous metastases (more than one month after diagnosis of HCC);
- pulmonary-only metastases \>5 and ≤10;
- metastases diameter ≤ 5 cm;
- intrahepatic tumors ≤5, and tumor burden ≤1/2 liver volume;
- PVTT type Vp≤3;
- patients underwent first-line system therapy failure, the first-line system included tyrosine kinase inhibitor (TKI), such as Sorafenib or Lenvatinib, with or without PD-1 or PDL1 inhibitor;
- the intrahepatic tumors were effectively controlled and pulmonary metastases were no progression, and the controlled intrahepatic tumors were defined as partial or stable response according to modified Response...
- locoregional therapy (including TACE or HAIC) were also included;
- Child-Pugh class A or B;
- PS 0 or 1;
- no history of other malignancies.
- under 18 years or over 75 years;
- metastases \>10
- non-lung metastases;
- incomplete clinical data;
- metastases diameter \> 5 cm;
- intrahepatic tumors \> 5, and tumor burden \> 1/2 liver volume;
- PVTT type Vp 4;
- lost to follow-up within 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Guanzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guanzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.